Profil
Thomas J.
Clarke is a Director of Vasogen, Inc. He was Chief Financial Officer of Visible Genetics, Inc. from 2000 to 2003.
Mr. Clarke was President, Chief Operating Officer and Chief Financial Officer of CCS Trexcom.
He has 25 years of experience in financial, accounting and operational management.
Mr. Clarke is a Certified Public Accountant.
Ehemalige bekannte Positionen von Thomas J. Clarke
Unternehmen | Position | Ende |
---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Direktor/Vorstandsmitglied | 23.10.2009 |
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Finanzdirektor/CFO | 01.01.2003 |
CCS Trexcom, Inc. | Präsident | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Health Technology |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
CCS Trexcom, Inc. |